Literature DB >> 19357701

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors.

M Garayoa1, J L Garcia, C Santamaria, A Garcia-Gomez, J F Blanco, A Pandiella, J M Hernández, F M Sanchez-Guijo, M-C del Cañizo, N C Gutiérrez, J F San Miguel.   

Abstract

It is an open question whether in multiple myeloma (MM) bone marrow stromal cells contain genomic alterations, which may contribute to the pathogenesis of the disease. We conducted an array-based comparative genomic hybridization (array-CGH) analysis to compare the extent of unbalanced genomic alterations in mesenchymal stem cells from 21 myeloma patients (MM-MSCs) and 12 normal donors (ND-MSCs) after in vitro culture expansion. Whereas ND-MSCs were devoid of genomic imbalances, several non-recurrent chromosomal gains and losses (>1 Mb size) were detected in MM-MSCs. Using real-time reverse transcription PCR, we found correlative deregulated expression for five genes encoded in regions for which genomic imbalances were detected using array-CGH. In addition, only MM-MSCs showed a specific pattern of 'hot-spot' regions with discrete (<1 Mb) genomic alterations, some of which were confirmed using fluorescence in situ hybridization (FISH). Within MM-MSC samples, unsupervised cluster analysis did not correlate with particular clinicobiological features of MM patients. We also explored whether cytogenetic abnormalities present in myelomatous plasma cells (PCs) were shared by matching MSCs from the same patients using FISH. All MM-MSCs were cytogenetically normal for the tested genomic alterations. Therefore we cannot support a common progenitor for myeloma PCs and MSCs.

Entities:  

Mesh:

Year:  2009        PMID: 19357701     DOI: 10.1038/leu.2009.65

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  66 in total

Review 1.  Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Authors:  Michaela R Reagan; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 2.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

Review 3.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

Review 4.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 5.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

6.  Stable changes in mesenchymal stromal cells from multiple myeloma patients revealed through their responses to Toll-like receptor ligands and epidermal growth factor.

Authors:  Meirav Pevsner-Fischer; Sarit Levin; Tal Hammer-Topaz; Yifat Cohen; Felix Mor; Gerard Wagemaker; Arnon Nagler; Irun Robert Cohen; Dov Zipori
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

7.  CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.

Authors:  Aldo M Roccaro; Yuji Mishima; Antonio Sacco; Michele Moschetta; Yu-Tzu Tai; Jiantao Shi; Yong Zhang; Michaela R Reagan; Daisy Huynh; Yawara Kawano; Ilyas Sahin; Marco Chiarini; Salomon Manier; Michele Cea; Yosra Aljawai; Siobhan Glavey; Elizabeth Morgan; Chin Pan; Franziska Michor; Pina Cardarelli; Michelle Kuhne; Irene M Ghobrial
Journal:  Cell Rep       Date:  2015-07-16       Impact factor: 9.423

8.  Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Yuping Wang; Sharmin Khan; Mohammad Heidaran; Ajai Pal; Xiaokui Zhang; Shuyang He; Andy Zeitlin; Stewart Abbot; Herbert Faleck; Robert Hariri; John D Shaughnessy; Frits van Rhee; Bijay Nair; Bart Barlogie; Joshua Epstein; Shmuel Yaccoby
Journal:  Stem Cells       Date:  2011-02       Impact factor: 6.277

9.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

Review 10.  Personalized therapies in the cancer "omics" era.

Authors:  Alberto Ocaña; Atanasio Pandiella
Journal:  Mol Cancer       Date:  2010-07-29       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.